SINGULAR GENOMICS SYSTEMS IN (OMIC)
$0.8596
Insights on Singular Genomics Systems Inc
Vs ISRG
In the last 1 year, Intuitive Surgical Inc has given 42.2% return, outperforming this stock by 114.6%
Performance
- $0.80$0.97$0.86
6.98%
Downside
Day's Volatility :17.29%
Upside
11.08%
- $0.76$4.80$0.86
11.06%
Downside
52 Weeks Volatility :84.06%
Upside
82.08%
Returns
| Period | SINGULAR GENOMICS SYSTEMS IN | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -51.0% | 2.1% | -5.8% |
6 Months | -48.85% | -6.4% | -2.1% |
1 Year | -72.37% | -1.4% | -7.8% |
3 Years | -96.32% | 25.7% | 17.4% |
Highlights
Market Capitalization | 67.1M |
Book Value | $3.34 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.12 |
Wall Street Target Price | 1.95 |
Profit Margin | 0.0% |
Operating Margin TTM | -5948.71% |
Return On Assets TTM | -18.69% |
Return On Equity TTM | -33.17% |
Revenue TTM | 1.6M |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -24.0K |
EBITDA | -94.1M |
Diluted Eps TTM | -1.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.44 |
EPS Estimate Next Year | -1.4 |
EPS Estimate Current Quarter | -0.35 |
EPS Estimate Next Quarter | -0.38 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 126.85%
Technicals Summary
Sell
Neutral
Buy
Singular Genomics Systems Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 SINGULAR GENOMICS SYSTEMS IN | -11.33% | -48.85% | -72.37% | -96.32% | -96.32% |
 Intuitive Surgical, Inc. | 4.17% | 17.82% | 42.25% | 59.8% | 95.15% |
 ResMed Inc. | -4.6% | -0.09% | 3.49% | 36.33% | 109.6% |
 Becton, Dickinson and Company | -0.41% | 1.61% | -2.89% | 1.3% | 9.0% |
 West Pharmaceutical Services Inc | -5.69% | 46.76% | 9.43% | 66.71% | 263.26% |
 Alcon AG | 5.86% | 16.84% | 4.6% | 25.97% | 36.63% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
SINGULAR GENOMICS SYSTEMS IN | 22.3 | NA | NA | -1.44 | -0.33 | -0.19 | 0.0 | 3.34 |
Intuitive Surgical, Inc. | 85.58 | 85.58 | 3.27 | 5.47 | 0.11 | 0.07 | 0.0 | 32.01 |
ResMed Inc. | 37.9 | 37.9 | 1.74 | 6.52 | 0.24 | 0.12 | 0.01 | 26.77 |
Becton, Dickinson and Company | 46.1 | 46.1 | 2.31 | 12.2 | 0.07 | 0.03 | 0.01 | 90.44 |
West Pharmaceutical Services Inc | 46.91 | 46.91 | 4.06 | 7.69 | 0.22 | 0.13 | 0.0 | 37.42 |
Alcon AG | 112.11 | 112.11 | NA | 2.65 | 0.02 | 0.02 | 0.0 | 40.29 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
SINGULAR GENOMICS SYSTEMS IN | Hold | $67.1M | -96.32% | 22.3 | 0.0% |
Intuitive Surgical, Inc. | Buy | $111.2B | 95.15% | 85.58 | 20.4% |
ResMed Inc. | Buy | $32.6B | 109.6% | 37.9 | 21.49% |
Becton, Dickinson and Company | Buy | $72.1B | 9.0% | 46.1 | 8.6% |
West Pharmaceutical Services Inc | Buy | $25.5B | 263.26% | 46.91 | 19.15% |
Alcon AG | Buy | $39.2B | 36.63% | 112.11 | 3.84% |
Institutional Holdings
Deerfield Management Co
8.96%UBS Group AG
6.53%ARCH VENTURE CORP
5.27%BlackRock Inc
4.93%Perceptive Advisors LLC
4.56%FMR Inc
2.95%
Company Information
singular genomics is a venture capital backed biotech company in la jolla, california. we foster a dynamic, fast paced, result oriented environment where we offer employees the opportunity to make a significant impact in a rapidly expanding company. singular genomics is inventing at the forefront of genomics, one of the world’s fastest growing industries. we are located in the center of the biotech hub on the torrey mesa close to the pacific ocean and next door to prestigious institutions like the salk institute, scripps, sanford burnham, and ucsd. we offer free gym membership, 401k plan, competitive health benefits, flexible vacation, and equity incentives, so you can grow as the company grows. we are working to accelerate genomics for the advancement of science and medicine and are passionate about the potential of genomics for improving human health.
Organization | SINGULAR GENOMICS SYSTEMS IN |
Employees | 276 |
CEO | Mr. Andrew Spaventa |
Industry | Healthcare |
